Medullary breast carcinoma

Experimental Oncology

Volumn 30, Issue 2, 2008, Pages 96-101

  Malyuchik, S S ^a   Kiyamova, R G ^a  

^a INSTITUTE OF MOLECULAR BIOLOGY AND GENETICS   (Ukraine)

Author keywords

Antigen; Immunoglobulin; Lymphoid infiltration; Medullary breast carcinoma

Indexed keywords

ACYLGLYCEROL LIPASE; ALPHA ACTININ; ANTIGEN; BETA 2 MICROGLOBULIN; BRCA1 PROTEIN; CD3 ANTIGEN; CD4 ANTIGEN; CD45RO ANTIGEN; CD57 ANTIGEN; CHECKPOINT KINASE 2; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYTOKERATIN 19; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GANGLIOSIDE GD3; GUANINE NUCLEOTIDE EXCHANGE FACTOR; HLA A2 ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON REGULATORY FACTOR 4; MYOSIN LIGHT CHAIN; PROTEIN BCL 2; PROTEIN P53; PROTEIN S 100; SECRETED FRIZZLED RELATED PROTEIN 1; SOMATOMEDIN BINDING PROTEIN; UNINDEXED DRUG; WNT PROTEIN;

BREAST CARCINOMA; CANCER GRADING; HUMAN; INVASIVE CARCINOMA; LYMPHOCYTIC INFILTRATION; MITOSIS; MORPHOLOGY; PROGNOSIS; REVIEW;

ANIMALS; ANTIGENS; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CARCINOMA, MEDULLARY; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY; LYMPHATIC METASTASIS; LYMPHOCYTES; NEOPLASM METASTASIS; NEOPLASMS; PROGNOSIS;

EID: 46749154719     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Ferlay J, Autier P, Boniol M, et al. Estimates of cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-92.
2. Lester J. Breast cancer in 2007: incidence, risk assessment, and risk reduction strategies. Clin J Oncol Nurs 2007; 11:619-22.
3. Li CI, Dating JR, Malone KE. Age-specific incidence ratesofin situ breast carcinomas by histologic type, 1980 to 2001. Cancer Epidemiol Biomarkers Prev 2005; 14: 1008-11.
4. van der Groep P, Bouter A, van der Zanden R, et al. Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data. J Clin Pathol 2006; 59:611-7.
5. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19:403-10.
6. Tavassoli FA, Devillee P. World Health Organisation Classification of tumours: pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press; 2003.
7. Shousha S. Medullary carcinoma of the breast and BRCA1 mutation. Histopathology 2000; 37: 182-5.
8. Ridolfi RL, Rosen PP, Port A, et al. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer 1977; 40: 1365-85.
9. Gjerstorff MF, Benoit VM, Laenkholm AV, et al. Identification of genes with altered expression in medullary breast cancer vs ductal breast cancer and normal breast epithelia. Int J Oncol 2006; 8: 1327-35.
10. Mayer JE, Karen EA, Lindfors K, et al. Medullary carcinoma of the breast: Mammographic US appearance. Radiology 1989; 170: 79-89.
11. Honrado E, Benýtez J, Palacio J. Histopathology of BRCA1- and BRCA2-associated breast cancer. Critical Rev in Oncol/HematoL 2006; 59: 27-39.
12. Pedersen L, Zedeler K, Hoick S, et al. Medullary carcinoma of the breast. Prevalence and prognostic importance of classical risk factors in breast cancer. Eur J Cancer 1995; 31:2289-95.
13. Hansen MH, Nielsen HV, Ditzel HJ. Translocation of an intracellular antigen to the surface of Medullary breast cancer cells early in apoptosis allow for an antigen-driven antibody response elicted by tumor infiltrating B cells. J Immun 2002; 169:2701-11.
14. Gaffey MJ, Frierson HF Jr, Mills SE, et al. Medullary carcinoma of the breast. Identification of lymphocyte subpopulations and their significance. Mod Pathol 1993; 6: 721-8.
15. Jensen V, Jensen ML, Kiaer H, et al. MIB-1 Expression in breast carcinomas with medullary features. Virchows Arch 1997; 431: 125-30.
16. Yakirevich E, Maroun L, Cohen O, et al. Apoptosis, proliferation, and fas (APO-1, CD95) / Fas ligand expression in medullary carcinoma of the breast. J Pathol 2000; 192: 166-73.
17. Bacus SS, Zelnick CR, Chin DM, et al. Medullary carcinoma is associated with expression of intercellular adhesion molecule-1. Implication to its morphology and its clinical behavior. Am J Pathol 1994; 145: 1337-48.
18. Ben-Baruch A. Host microenvironment in breast cancer development inflammatory cells, cytokines and chemokines in breast cancer progression: Reciprocal tumor-microenvironment interactions. Breast Cancer Res 2003; 5: 31-6.
19. Leek RD, Harris AL. Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia 2002; 7: 177-89.
20. Crowther M, Brown NJ, Bishop ET, Lewis CE. Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors. J Leuk Biol 2001;70:478-90.
21. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-45.
22. De Chiara A, Losito S, Terracciano L, et al. Primary plasmacytoma of the breast. Arch Pathol Lab Med 2001; 125: 1078-80.
23. Serafi AA, Delgado M, Nambo J, et al. Primary breast lymphoma: results of a controlled clinical trial. Oncology 2005; 69: 256-60.
24. Sutcliffe SB, Gospodarowicz MK. Clinical features and management of localized extranodal lymphomas. In Keating A, Armitage J, Burnet A, Newland A (eds): Haema-tological Oncology. Cambridge: Cambridge University Press 1992; 2: 189-223.
25. Bobrow LG, Richards MA, Happerfield LC, et al. Breast lymphomas: A clinicopathologic review. Hum Pathol 1993; 24: 274-8.
26. Jeon HJ, Akagi T, Hoshida Y, et al. Primary non-Hodgkin malignant lymphoma ofthe breast. An immunohistochemical study of seven patients and literature review of 152 patients with breast lymphoma in Japan. Cancer 1991; 70: 2451-9.
27. Hussong JW, Perkins SL, Schnitzer B, et al. Extramedullar plasmacytoma. A form of marginal zone cell lymphoma? Am J Clin Pathol 1999; 111: 111-6.
28. Tot T. The cytokeratin profile of medullary carcinoma of the breast. Histopathology 2000; 37: 175-81.
29. Yoshida S, Nakamura N, Sasaki Y, et al. Primary breast diffuse large B-cell lymphoma shows a non-germinal center B-cell phenotype. Modern Pathology 2005; 18: 398-405.
30. Scanlan MJ, Jäger D. Challenges to the development of antigen-specific breast cancer vaccines. Breast Cancer Res 2001;3:95-8.
31. Zhang NZB, Demetrikopoulos MK, Kitson RP, et al. Evidence for involvement of B lymphocytes in the surveillance of lung metastasis. Cancer Res 1999; 59: 1080-9.
32. Coronella, JA, Hersh EM. Naturally occurring B-cell responses to breast cancer. Cancer Immunol. Immunother 2003;52:715-38.
33. Hodge JW. Carcinoembryonic antigen as a target for cancer vaccines. Cancer Immunol Immunother 1996; 43: 127-34.
34. Morse MA, Deng Y, Coleman D, et al. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 1999; 5: 1331-8.
35. Jager D, Unkelbach M, Frei C, et al. Identification of tumor-restricted antigens NY-BR-1, SCP-1, and a new cancer/ testis-like antigen NW-BR-3 by serological screening of a testicular library with breast cancer serum. Cancer Immun 2002; 2: 5.
36. Feinmesser M, Sulkes A, Morgenstern S, et al. HLA-DR and β2 microglobulin expression in medullary and atypical medullary carcinoma of the breast: histopathologically similar but biologically distinct entities. J Clin Pathol 2000; 53: 286-91.
37. Kotlan B, Simsa P, Teillaud JL, et al. Novel ganglio-side antigen identified by B cells in human medullary breast carcinomas: The proof of principle concerning the tumor-infiltrating B lymphocytes. J Immunol 2005; 175: 2278-85.
38. McKallip R, Ruixiang L, Ladisch S. Tumorgangliosides inhibit the tumor-specific immune response. Immunol 1999; 163: 3718-26.
39. Mitchell MS. Cancer vaccines, a critical review-part II. Curr Opin Invest Drugs 2002; 3: 150-8.
40. Moutel S, Birkle S, Laurence V, Michon, et al. Generation and characterization of a mouse single-chain antibody fragment specific for disialoganglioside (GD2). Hybridoma 1997; 16: 335-46.
41. Ingvarsson S. Molecular Genetics of Breast Cancer. Int J Hum Genet 2003; 3: 69-78.
42. Szabo CI, King MC. Population genetics of BRCA1 and BRCA2. Am J Hum Genet 1997; 60: 1013-20.
43. Harkin DP, Bean JM, Miklos D, et al. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell 1999; 97: 575-86.
44. Brodie SG, Deng CX. BRCA1-associated tumorigenesis: what have we learned from knockout mice? Trends Genet 2001; 17: 18-22.
45. MacLachlan TK, Dash BC, Dicker DT, El-Deiry WS. Repression of BRCA1 through a feedback loop involving p53. J Biol Chem 2000; 275: 1869-75.
46. Xu B, Kim S, Kastan MB. Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation. Mol Cell Biol 2001; 21: 3445-50.
47. Lea M, Starita and Jeffrey D, Parvin. The multiple nuclear functions of BRCA1: transcription, ubiquitination and DNA repair. Curr Opin Cell Biol 2003; 15: 345-50.
48. Foulkes WD, Metcalfe K, Sun P, et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 2004; 10: 2029-34.
49. Putti TC, Abd El-Rehim DM, Rakha EA, et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol 2005; 18: 3526-50.
50. Eerola H, Heikkila P, Tamminen A, et al. Relationship of patients age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 2005; 7: 465-9.
51. de Cremoux P, Salomon AV, Liva S, et al. p53 mutation as a genetic trait of typical medullary breast carcinoma. J Natl Cancer Inst 1999; 91: 641-3.
52. Grushko TA, Blackwood MA, Schumm PL, et al. Molecularcytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res 2002; 62: 1481-8.
53. Ross LS, Linette GP, Stec LS, et al. Breast cancer biomarkers and molecular medicine part 2. Expert Rev Mol Diagn 2004; 4: 169-88.
54. Xu R, Feiner H, Li P, et al. Differential amplification and overexpression of HER-2/neu, p53, MIB1, and estrogen receptor/progesterone receptor among medullary carcinoma, atypical medullary carcinoma, and high-grade invasive ductal carcinoma of breast archives of pathology and laboratory medicine 2003 127; 11: 1458-64.
55. Sullivan A, Yuille M, Repellin C, et al. Concomitant inactivation of p53 and Chk2 in breast cancer. Oncogene 2002; 21: 1316-24.
56. Verhoeven ICL, Hillen HFP, Wagstaff J, et al. Agiogenic profile of breast carcinoma determines leukocyte infiltration. Clin Cancer Res 2004; 10: 7171-8.
57. Salomon AV, Gruel N, Lucchesi C, et al. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res 2007; 9: 24.
58. Rijsewijk F, Schuermann M, Wagenaar E, et al. The Drosophila homolog of the mouse mammary oncogene int-1 is identical to the segment polarity gene wingless. Cell 1987; 50:649-57.
59. Jensen V, Jensen ML, KiaerH, et al. MIB-1 expression in breast carcinomas with medullary features: an immuno-histological study including correlations with p53 and bcl-2. VirchowsArch 1997; 431: 125-30.
60. Adam PJ, Berry J, Loader JA, et al. Arylamine N-Acetyltransferase-1 Is Highly Expressed in Breast Cancers and Conveys Enhanced Growth and Resistance to Etoposide in Vitro. Mol Cancer Res 2003; 1: 826-35.
61. Zhou J, Zhong Y. Breast cancer immunotherapy. Cell Mol Immunol 2004; 1: 247-55.